Elective Neck Dissection for cT1‐4 N0M0 Head and Neck Verrucous Carcinoma
Otolaryngology–Head and Neck Surgery · 2023-11 · 169 (5) · 1187-1199
DOI: 10.1002/ohn.374 ↗Kurz gefasst
Fachartikel in der Zeitschrift Otolaryngology–Head and Neck Surgery, online erschienen am 06.06.2023. Verfasst von Aman M Patel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, USA. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Head and Neck Neoplasms, Carcinoma, Verrucous. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 62 Literaturangaben.
Abstract (Originalsprache)
Objective
To investigate the survival benefit of elective neck dissection (END) over neck observation in cT1‐4 N0M0 head and neck verrucous carcinoma (HNVC). Study Design Retrospective cohort study.
Setting
The 2006 to 2017 National Cancer Database.
Methods
Patients with surgically resected cT1‐4 N0M0 HNVC were selected. Linear, binary logistic, Kaplan‐Meier, and Cox proportional hazards regression models were utilized.
Results
Of 1015 patients satisfying inclusion criteria, 223 (22.0%) underwent END. The majority of patients were male (55.4%) and white (91.0%) with disease of the oral cavity (67.6%) classified as low grade (90.0%) and cT1‐2 (81.8%). The minority of ENDs (4.0%) detected occult nodal metastases. The rate of END increased from 2006 to 2017 for both cT1‐2 (16.3% vs 22.0%, p = .126, R 2 = 0.405) and cT3‐4 (41.7% vs 70.0%, p = .424, R 2 = 0.232) disease but these trends were not statistically significant. Independent predictors of undergoing END included treatment at an academic facility (adjusted odds ratio [aOR]: 1.75, 95% confidence interval [CI]: 1.19‐2.55), cT3‐4 disease (aOR: 3.31, 95% CI: 2.16‐5.07), and tumor diameter (aOR: 1.09, 95% CI: 1.01‐1.19) ( p < 0.05). The 5‐year overall survival (OS) of patients treated with and without END was 71.3% and 70.6%, respectively ( p = .661). END did not significantly reduce the 5‐year hazard of death (adjusted hazard ratio: 1.25, 95% CI: 0.91‐1.71, p = .172). END did not significantly improve 5‐year OS in univariate and multivariate analyses stratified by several patient, facility, tumor, and treatment characteristics.
Conclusion
END does not confer an appreciable survival benefit in HNVC, even after stratifying univariate and multivariate analyses by several patient, facility, tumor, and treatment characteristics. Level of Evidence Level 4.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
- Department of Otolaryngology-Head and Neck Surgery, Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA.
ORCID-Profile: Aman M Patel
Zitieren
APA
Patel, A. M., Vedula, S., Haleem, A., Choudhry, H. S., Tseng, C. C., & Park, R. C. W. (2023). Elective Neck Dissection for cT1‐4 N0M0 Head and Neck Verrucous Carcinoma. Otolaryngology–Head and Neck Surgery, 169(5), 1187-1199. https://doi.org/10.1002/ohn.374
Vancouver
Patel AM, Vedula S, Haleem A, Choudhry HS, Tseng CC, Park RCW. Elective Neck Dissection for cT1‐4 N0M0 Head and Neck Verrucous Carcinoma. Otolaryngology–Head and Neck Surgery. 2023;169(5):1187-1199. doi:10.1002/ohn.374
BibTeX
@article{Patel2023,
author = {Patel, Aman M and Vedula, Sudeepti and Haleem, Afash and Choudhry, Hassaam S and Tseng, Christopher C and Park, Richard Chan Woo},
title = {Elective Neck Dissection for cT1‐4 N0M0 Head and Neck Verrucous Carcinoma},
journal = {Otolaryngology–Head and Neck Surgery},
year = {2023},
volume = {169},
number = {5},
pages = {1187--1199},
doi = {10.1002/ohn.374}
}
EUVIMED